EnVivo's EVP-6124 meets AD endpoint

EnVivo Pharmaceuticals Inc. (Watertown, Mass.) said once-daily oral EVP-6124 met the co-primary endpoints of improving cognition and clinical function at week 23 vs. placebo in a Phase IIb trial to treat mild to moderate Alzheimer's disease (AD). Cognition was measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale-13 (ADAS-Cog-13), while clinical function was measured by Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB).

The trial, which enrolled 409 patients, included both patients who were and were not receiving stable background therapy with an acetylcholinesterase (AChE) inhibitor ( Aricept donepezil or Exelon rivastigmine). Data were presented at the Alzheimer's Association International meeting in Vancouver. EVP6124 is a nicotinic acetylcholine receptor alpha 7 (CHRNA7) agonist. ...